Breaking News

You are here » Indian-Commodity  :  Top News  :  Shiva Cement to sell integrated cement plant in Orissa: Report

10-Oct2016

Shiva Cement to sell integrated cement plant in Orissa: Report

Shiva Cement is reportedly planning to sell its integrated cement plant in Orissa. The company is in talks with OCL India among others to sell its Orissa cement unit. The deal is valued at an enterprise value of Rs 250 crore.

Shiva Cement is engaged in manufacturing of cement and allied products. Its plants are located at Kalunga and Sundargarh in Orissa. The company has a combined installed capacity of 177,000 tonnes per annum.


Related News

View all news

Crude oil futures settle higher on Thursday

Extending gains for second straight session, crude oil futures settled higher on Thursday, despite official data from the Energy Information Administration (EIA) showing a bigger than expected increase......

Gold futures settle higher on weak dollar

Gold futures settled higher on Wednesday, rebounding from previous session's lowest finish. The yellow metal marked biggest one-day gain in nearly two weeks, as the dollar eased by 0.2 percent after hitting......

Copper futures end higher on Wednesday

Copper futures ended higher on Wednesday. Meanwhile, base metals on London Metal Exchange held steady as weak retail sales data from top consumer China took the shine off upbeat industrial output and investment......

Top News

View all news

Karnataka Bank launches CASA campaign

Karnataka Bank has launched Current & Savings Accounts campaign (CASA) of FY 2018-19 and introduced a new SB scheme 'KBL SB - TASC' a specialized product for Trusts/Associates/Societies/Clubs.Under......

M&M's arm opens manufacturing hub in Bengaluru

Mahindra & Mahindra's (M&M) subsidiary -- Mahindra Electric Mobility has opened its electric technology manufacturing hub set up with an investment of Rs 100 crore in Bengaluru. The plant......

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific......